Beta-blockers in the management of coronary artery disease: are we on the verge of a new paradigm shift?

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Recent Advances in Cardiovascular Drug Discovery (Formerly Recent Patents on Cardiovascular Drug Discovery)

• Publication date

  2015-01-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/1574890109666140901144210PMID 25174339
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Beta-blocker use in ST-segment elevation myocardial infarction in the reperfusion era (GRACE).

  2014cited by this paper
• Long-term benefit of early pre-reperfusion metoprolol administration in patients with acute myocardial infarction: results from the METOCARD-CNIC trial (Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction).

  2014cited by this paper
• Ivabradine, coronary artery disease, and heart failure: beyond rhythm control

  2014cited by this paper
• Benefit of Immediate Beta-Blocker Therapy on Mortality in Patients With ST-Segment Elevation Myocardial Infarction*

  2013cited by this paper
• Effect of Early Metoprolol on Infarct Size in ST-Segment–Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention: The Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) Trial

  2013cited by this paper
• 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  2013cited by this paper
• 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.

  2013cited by this paper
• Third universal definition of myocardial infarction

  2013cited by this paper
• β-blocker use in patients after percutaneous coronary interventions: one size fits all? Worse outcomes in patients without myocardial infarction or heart failure.

  2013cited by this paper
• Beta-Adrenergic Receptors, from Their Discovery and Characterization through Their Manipulation to Beneficial Clinical Application

  2012cited by this paper
• Long-term beta blockers for stable angina: systematic review and meta-analysis

  2012cited by this paper
• β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease.

  2012cited by this paper
• Heart rate: a forgotten link in coronary artery disease?

  2011cited by this paper
• Structural insights into adrenergic receptor function and pharmacology.

  2011cited by this paper
• THE ROLE OF β-ADRENERGIC RECEPTORS IN HEART FAILURE: DIFFERENTIAL REGULATION OF CARDIOTOXICITY AND CARDIOPROTECTION.

  2011cited by this paper
• Beta-blockers: focus on mechanism of action Which beta-blocker, when and why?

  2010cited by this paper
• The structure and function of G-protein-coupled receptors

  2009cited by this paper
• Do β-blockers reduce short-term mortality following acute myocardial infarction? A systematic review and meta-analysis

  2008cited by this paper
• β-Adrenergic Blockers: A 50-Year Historical Perspective

  2008cited by this paper
• Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.

  2005cited by this paper
• Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina.

  2005cited by this paper
• ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients Wi

  2004cited by this paper
• Impact of intravenous beta-blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction.

  2004cited by this paper
• Cardiovascular drug class specificity: β-blockers

  2004cited by this paper
• Effects of prior beta-blocker therapy on clinical outcomes after primary coronary angioplasty for acute myocardial infarction

  2003cited by this paper
• Anti-Ischemic Effects of Ivabradine, a Selective Heart Rate-Reducing Agent, in Exercise-Induced Myocardial Ischemia in Pigs

  2003cited by this paper
• Effect of carvedilol on survival in severe chronic heart failure.

  2001cited by this paper
• Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.

  2001cited by this paper
• Effects of Controlled-Release Metoprolol on Total Mortality, Hospitalizations, and Well-being in Patients with Heart Failure: The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)

  2000cited by this paper
• β-Adrenergic Blocking Agents in Heart Failure: Benefits of Vasodilating and Nonvasodilating Agents According to Patients' Characteristics: A Meta-analysis of Clinical Trials

  2000cited by this paper
• The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.

  1999cited by this paper
• Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice.

  1999cited by this paper
• ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Chronic Stable Angina).

  1999cited by this paper
• Opposing Effects of β1- and β2-Adrenergic Receptors on Cardiac Myocyte Apoptosis Role of a Pertussis Toxin–Sensitive G Protein

  1999cited by this paper
• Meta-analysis of Trials Comparing β-Blockers, Calcium Antagonists, and Nitrates for Stable Angina

  1999cited by this paper
• Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries.

  1998cited by this paper
• The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle.

  1998cited by this paper
• Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS)

  1996cited by this paper
• Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET Study Group.

  1996cited by this paper
• Functional coupling of the beta 2-adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes.

  1995cited by this paper
• Nitric oxide donor SIN-1 inhibits mammalian cardiac calcium current through cGMP-dependent protein kinase.

  1995cited by this paper
• Effects of Treatment on Outcome in Mildly Symptomatic Patients With Ischemia During Daily Life: The Atenolol Silent Ischemia Study (ASIST)

  1994cited by this paper
• Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study.

  1991cited by this paper
• Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification.

  1988cited by this paper
• Efficacy of nifedipine and metoprolol in the early treatment of unstable angina in the coronary care unit: findings from the Holland Interuniversity Nifedipine/metoprolol Trial (HINT).

  1987cited by this paper
• Effect of the addition of propranolol to therapy with nifedipine for unstable angina pectoris: a randomized, double-blind, placebo-controlled trial.

  1986cited by this paper
• Efficacy of carvedilol (BM 14,190), a new beta-blocking drug with vasodilating properties, in exercise-induced ischemia.

  1985cited by this paper
• Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. The MIAMI Trial Research Group.

  1985cited by this paper
• Beta blockade during and after myocardial infarction: an overview of the randomized trials.

  1985cited by this paper
• The Göteborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction.

  1983cited by this paper
• Timolol‐related Reduction in Mortality and Reinfarction in Patients Ages 65‐75 Years Surviving Acute Myocardial Infarction

  1982cited by this paper
• Cardiovascular and respiratory effects of cannabis in cat and rat

  1973cited by this paper
• The action of ICI-66082 on the heart.

  1973cited by this paper
• A new type of cardioselective adrenoceptive blocking drug.

  1973cited by this paper
• Effect of atenolol in angina pectoris of effort.

  1972cited by this paper
• A new beta adrenergic blocking agent, propranolol, in the treatment of angina pectoris.

  1968cited by this paper
• Unwanted effects of propranolol.

  1966cited by this paper
• Effect of Propranolol (Inderal) in Angina Pectoris: Preliminary Report

  1964cited by this paper
• Preliminary CommunicationsA NEW ADRENERGIC: BETA-RECEPTOR ANTAGONIST

  1964cited by this paper
• Effect of Pronethalol in Angina Pectoris

  1963cited by this paper

• 20 – The Medical Treatment of Stable Angina

  2018cites this paper
• Advancements in pharmacotherapy for angina

  2017cites this paper
• Elevated heart rate and nondipping heart rate as potential targets for melatonin: a review

  2016cites this paper
• Aspirin and the risk of cardiovascular events in atherosclerosis patients with and without prior ischemic events

  2016cites this paper
• Intravenous β-blockers for patients undergoing primary percutaneous coronary intervention: A meta-analysis of randomized trials.

  2016cites this paper
• Experimental and early investigational drugs for angina pectoris

  2016cites this paper